Citations

Showing 10 of 108152 citations.

A4 Pulley Reconstruction Using the Superficialis Oblique Flap and the Transverse Double Loop Techniques
Galán, Ricardo, Manrique, Oscar J. , Bustos, Samyd S. , Arango, Diego, Correa, Diana , Terán, Diego, Vergara, María, Moran, Steven L. , Bustos, S S

Mayo Clinic

Annals of Plastic Surgery | July 16, 2021 | Volume: 87 | Issue: 6 | Pages: 650-656

10.1097/sap.0000000000002796 | PMID 34270466 Get It

Background The pulley system plays an important role in flexion mechanism. Reconstruction after trauma can be challenging. Numerous techniques have been described with several drawbacks. Herein, we describe the superficialis flap oblique technique for A4 pulley reconstruction using an animal model. Methods Forty-two fresh legs of 21 eight-week-old chickens were used to evaluate the maximum flexion angle (MFA) and force at maximum flexion (FMF) in intact and sectioned A4 pulley equivalents of the third digit after reconstruction with the transverse double loop (TDL) technique and the superficialis oblique flap (SOF) technique. Biomechanical measurements were obtained in an exclusively designed instrument. Descriptive statistics were reported, and mean differences between the reconstructive techniques were analyzed. Results Intact and severed A4 pulley equivalent average MFA were 96.50° ± 1.70° and 115.60° ± 1.50°, respectively. Average FMF were 8.16 ± 0.23 psi with the intact pulley and 6.92 ± 0.20 psi with the sectioned pulley (P < 0.001). After reconstruction with TDL and SOF techniques, the legs reached an average MFA at the distal interphalangeal joint of 98.13° ± 1.20° and 96.90° ± 1.30°, respectively. Mean MFA difference was 1.23° (P = 0.03). Force at maximum flexion was 8.12 psi and 8.10 psi for the TDL and SOF techniques (P = 0.6), respectively. Conclusions The authors believe that SOF technique for A4 pulley reconstruction can be used as first option when available, taking into account its theoretical advantages and its proven biomechanical characteristics. Long-term functional results should be assessed to translate these results into the clinical setting.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Miguel, Jesús F. San , Paiva, Bruno , Kumar, Shaji , Mateos, María‐Victoria , Usmani, Saad Z. , Cook, Gordon , Cavo, Michèle , Quach, Hang , Ukropec, Jon, Ramaswami, Priya, Pei, Huiling , Qi, Mia, Sun, Steven , Wang, Jianping , Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Rampelbergh, Rian Van , Kudva, Anupa, Kobos, Rachel, Qi, Ming , San-Miguel, Jesus , Paiva, Bruno , Kumar, Shaji K , Mateos, María-Victoria , Quach, Hang , Cook, Gordon , Usmani, Saad , Avet‐Loiseau, Hervé , Dimopoulos, Meletios Α. , Facon, Thierry T.F. , Touzeau, Cyrille , Jakubowiak, Andrzej , Bahlis, Nizar Jacques

Mayo Clinic

Blood | July 16, 2021 | Volume: 139 | Issue: 4 | Pages: 492-501

10.1182/blood.2020010439 | PMID 34269818 Get It

Abstract In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10−5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).
Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community
AbouEzzeddine, Omar F. , Saenger, Amy K., Jaffe, Allan S. , Harmon, David M , McKie, Paul M. , AbouEzzeddine, Omar F , Harmon, David , Scott, Christopher G. , Jaffe, Allan S.

Mayo Clinic

Biomarkers | July 16, 2021 | Volume: 26 | Issue: 7 | Pages: 639-646

10.1080/1354750x.2021.1956590 | PMID 34269635 Get It

Venous Causes of Pulsatile Tinnitus: Clinical Presentation, Clinical and Radiographic Evaluation, Pathogenesis, and Endovascular Treatments: A Literature Review
Essibayi, Muhammed Amir , Oushy, Soliman , Lanzino, Giuseppe , Brinjikji, Waleed , Oushy, Soliman H , Lanzino, Giuseppe , Essibayi, Muhammed Amir

Mayo Clinic

Neurosurgery | July 16, 2021 | Volume: 89 | Issue: 5 | Pages: 760-768

10.1093/neuros/nyab299 | PMID 34392338 Get It

Abstract Tinnitus is an abnormal perception of a sound without external stimulation. Venous pulsatile tinnitus (VPT) is a specific form of tinnitus characterized by an objective and often subjective bruit that occurs as a result of localized venous abnormalities. Clinical evaluation relies on sound quality, duration, and precipitating factors. Idiopathic intracranial hypertension (IIH) and transverse sinus stenosis (TSS) are among the most common causes of VPT. Other causes include sigmoid sinus wall abnormalities (SSWAs), jugular vein anomalies (JVAs), and emissary veins anomalies. These anomalies can be detected on magnetic resonance imaging, magnetic resonance angiography/magnetic resonance venography, and high-resolution temporal bone computed tomography. The pathogenesis behind the VPT includes turbulent blood flow as a result of luminal stenosis or abnormal dilation, amplification of internal sound due to temporal bone defects, and abnormal position of the venous sinus system structures adjacent to the bony structures of the auditive apparatus. Based on these theories, different interventional treatment modalities can be applied to treat the underlying causes. Endovascular treatments have shown high efficacy and safety among those treatments which include stenting of the lateral sinus stenosis in IIH and TSS, coiling of the SSWA and JVA, and embolization of emissary veins anomalies. Further studies are needed to understand the natural history of these anomalies and the efficacy of treatments of VPT, which—unlike other types of tinnitus—can be cured with proper treatment.
Measurable Thoracic Motion Remains at 1 Year Following Anterior Vertebral Body Tethering, with Sagittal Motion Greater Than Coronal Motion
Buyuk, Abdul Fettah , Milbrandt, Todd A. , Mathew, Smitha , Larson, A. Noelle , Mathew, Smitha E , Larson, A Noelle , Buyuk, Abdul Fettah , Milbrandt, Todd A

Mayo Clinic

Journal of Bone and Joint Surgery | July 16, 2021 | Volume: 103 | Issue: 24 | Pages: 2299-2305

10.2106/jbjs.20.01533 | PMID 34270505 Get It

Background: Anterior vertebral body tethering is an alternative to fusion surgery for the treatment of adolescent idiopathic scoliosis (AIS) that is purported to preserve spinal motion. There is limited information regarding the measurable motion that is maintained over the instrumented levels following thoracic anterior vertebral body tethering surgery in humans. The purpose of the present study was to assess radiographic spinal motion 1 year after anterior vertebral body tethering. Methods: As part of a prospective U.S. Food and Drug Administration investigational device exemption study, 32 patients were treated with thoracic anterior vertebral body tethering. At 1 year postoperatively, patients were evaluated with standing flexion-extension and side-bending radiographs in a microdose biplanar slot scanning imaging system. The angle subtended by the screws at the upper instrumented vertebra (UIV) and lower instrumented vertebra (LIV) was measured on left and right-bending radiographs to evaluate the coronal arc of motion and was compared with preoperative values over the same levels. At 1 year postoperatively, the sagittal Cobb angle was measured over the instrumented levels on flexion and extension radiographs. Results: Side-bending radiographs revealed that the mean angle subtended by the screws changed from 15° ± 8° on left-bending radiographs to 8° ± 6° on right-bending radiographs. The mean coronal arc of motion on bending was 7° ± 6°, with 20 (62.5%) of 32 patients having a coronal arc of motion of >5°. The mean preoperative coronal arc of motion over the instrumented segments was 30° ± 9°. On flexion-extension lateral radiographs made at 1 year postoperatively, the mean kyphotic angle over the instrumented segments was 33° ± 13° in flexion and 11° ± 14° in extension, for a mean postoperative arc of motion of 21° ± 12° between flexion and extension radiographs. Conclusions: At 1 year following thoracic anterior vertebral body tethering for the treatment of AIS, the thoracic spine showed a measurable range of coronal and sagittal plane motion over the instrumented levels without evidence of complete autofusion. Motion in the coronal plane decreased by 77% following anterior vertebral body tethering. These findings provide proof of concept that sagittal spinal motion is preserved after thoracic anterior vertebral body tethering, although the functional importance remains to be determined. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Informed Consent for the Orthopaedic Surgeon
Jildeh, Toufic R. , Abbas, Muhammad J. , Hengy, Meredith , O’Brien, Hannah , Gani, G. Sal , Okoroha, Kelechi R. , Hengy, Meredith H , O’Brien, Hannah

Mayo Clinic

JBJS Reviews | July 16, 2021 | Volume: 9 | Issue: 7 | Pages: No page available

10.2106/jbjs.rvw.21.00018 | PMID 34270504 Get It

» In the United States, orthopaedic surgeons have a legal obligation to obtain informed consent from patients before performing surgery; it is a process that includes a signed written document. » There are specific legal requirements that vary somewhat by state but generally include disclosure and documentation of the diagnosis, an explanation of the recommended procedure, a conversation about the risks and benefits of the procedure, and a discussion about alternative treatments. » Inadequate disclosure of risks and alternatives is associated with increased indemnity risk. » Studies have shown that many consent processes and forms are suboptimal.
Evaluation and Management of Autonomic Dysreflexia and Other Autonomic Dysfunctions: Preventing the Highs and Lows
Linsenmeyer, Todd A. , Elliott, Stacy , Gorman, Peter H. , Vogel, Lawrence C. , Wecht, Jill M. , Clay, Sarah, Gorman, Peter , Krassioukov, Andrei V. , Beck, Lisa A. , Kirshblum, Steven

Mayo Clinic

The Journal of Spinal Cord Medicine | July 16, 2021 | Volume: 44 | Issue: 4 | Pages: 631-683

10.1080/10790268.2021.1925058 | PMID 34270391 Get It

Collaborative Writing Projects: Set Yourself up for Success
Catanzano, Tara, Robbins, Jessica B. , Schwartz, Fides R. , Rajiah, Prabhakar , Wang, Sherry S. , Soloff, Erik V. , Folio, Les , Rajiah, Prabhakar , Nandwana, Sadhna B.

Mayo Clinic

Journal of Computer Assisted Tomography | July 16, 2021 | Volume: 45 | Issue: 4 | Pages: 495-499

10.1097/rct.0000000000001187 | PMID 34270477 Get It

Abstract This article will review critical components for the successful completion of a multi-institution, multiauthor collaborative paper. Best practices for the creation and publication of a collaborative paper will be addressed.
MASiVar: Multisite, multiscanner, and multisubject acquisitions for studying variability in diffusion weighted MRI
Cai, Leon Y. , Kanakaraj, Praitayini , Nath, Vishwesh , Newton, Allen T. , Edmonson, Heidi A. , Luci, Jeffrey J. , Conrad, Benjamin , Price, Gavin R. , Hansen, Colin B. , Kerley, Cailey I. , Ramadass, Karthik , Yeh, Fang‐Cheng , Garyfallidis, Eleftherios , Descoteaux, Maxime , Rheault, François , Conrad, Benjamin N , Landman, Bennett A , Yang, Qi , Kang, Hakmook , Schilling, Kurt G.

Mayo Clinic

Magnetic Resonance in Medicine | July 16, 2021 | Volume: 86 | Issue: 6 | Pages: 3304-3320

10.1002/mrm.28926 | PMID 34270123 Get It

Purpose Diffusion‐weighted imaging allows investigators to identify structural, microstructural, and connectivity‐based differences between subjects, but variability due to session and scanner biases is a challenge. Methods To investigate DWI variability, we present MASiVar, a multisite data set consisting of 319 diffusion scans acquired at 3 T from b = 1000 to 3000 s/mm 2 across 14 healthy adults, 83 healthy children (5 to 8 years), three sites, and four scanners as a publicly available, preprocessed, and de‐identified data set. With the adult data, we demonstrate the capacity of MASiVar to simultaneously quantify the intrasession, intersession, interscanner, and intersubject variability of four common DWI processing approaches: (1) a tensor signal representation, (2) a multi‐compartment neurite orientation dispersion and density model, (3) white‐matter bundle segmentation, and (4) structural connectomics. Respectively, we evaluate region‐wise fractional anisotropy, mean diffusivity, and principal eigenvector; region‐wise CSF volume fraction, intracellular volume fraction, and orientation dispersion index; bundle‐wise shape, volume, fractional anisotropy, and length; and whole connectome correlation and maximized modularity, global efficiency, and characteristic path length. Results We plot the variability in these measures at each level and find that it consistently increases with intrasession to intersession to interscanner to intersubject effects across all processing approaches and that sometimes interscanner variability can approach intersubject variability. Conclusions This study demonstrates the potential of MASiVar to more globally investigate DWI variability across multiple levels and processing approaches simultaneously and suggests harmonization between scanners for multisite analyses should be considered before inference of group differences on subjects.
Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers
Kotwal, Anupam , Ryder, Mabel , Kudva, Yogish C , Ryder, Mabel

Mayo Clinic

Current Opinion in Endocrinology, Diabetes & Obesity | July 16, 2021 | Volume: 28 | Issue: 5 | Pages: 517-524

10.1097/med.0000000000000664 | PMID 34269714 Get It

Purpose of review Our goal is to review pertinent data evaluating the association between immune checkpoint inhibitor (ICI)-induced endocrine dysfunction and survival in cancer patients as well as to understand the potential molecular links between these. Recent findings ICIs have revolutionized cancer therapy but have also led to multiple immune-related adverse events (irAEs). Studies have demonstrated a link between the development of irAEs and improved survival, suggesting that ICI-induced antitumor immunity and autoimmunity are coupled. Thyroid irAEs are most frequently and strongly associated with improved survival, particularly in the context of overt thyroid dysfunction. Other endocrine irAEs, such as hypophysitis and diabetes are quite rare wherein the treatment approach or the disease process itself may mitigate improvement in survival. Preclinical and translational data indicate a role for CD4+ T cells, regulatory T cells and/or cytokines mediating irAEs, including thyroiditis. Summary The development of irAEs is associated with improved tumor responses and survival in cancer patients. Thyroid irAEs, alone or in combination with other irAEs, are most strongly associated with improved outcomes. Biomarkers of response to ICIs are lacking, despite well-characterized pathologic and genomic susceptibilities predicting ICI efficacy. Early detection of thyroid irAEs may identify patients most likely to have durable antitumor response to ICIs. Although irAEs and antitumor immunity appear ‘coupled’, translational studies indicate the potential for their ‘uncoupling’, which could enable antitumor efficacy with greater safety margins.